Although no biosimilar has earned an interchangeable designation by the FDA to date, the distinction could garner more biosimilar uptake. In a presentation during the American Conference Institute’s Summit on Biosimilars, held June 25-27 in New York, New York, various stakeholders discussed how interchangeability is the future of the space.
Although no biosimilar has earned an interchangeable designation by the FDA to date, the distinction could garner more biosimilar uptake. In a presentation during the American Conference Institute (ACI)’s Summit on Biosimilars, held June 25-27 in New York, New York, various stakeholders discussed how interchangeability is the future of the space.
Ha Kung Wong, JD, partner at Fitzpatrick, Cella, Harper & Scinto, noted that the lack of biosimilar uptake within the United States, offering a seemingly low return on investment, could be due to the fact that none of the biosimilars are substitutable at the pharmacy level. “Analysts have predicted that by the end of 2018, infliximab biosimilars will only get 10% of the total infliximab market. In contrast, in Europe these biosimilars have 53% of the market.”
Concerns around interchangeable biosimilars stem from many patient groups and other industry members fearing that the substitution would be made at a pharmacy level without notification to the patient or physician and would result in a clinically different or harmful result. To pre-emptively address this concern, 44 states thus far and Puerto Rico have passed policies that cover a multitude of concerns, but largely require the notification of a physician that the substitution is being made within a timely manner.
However, Bruce Leicher, senior vice president and general counsel at Momenta Pharmaceuticals, said that there are certain changes seen in reference products throughout a manufacturing life cycle, even though these products are viewed as interchangeable. “Historically, there’s been a view that reference products are interchangeable when we go through manufacturing changes, but you will see significant differences between different lots of reference products.”
Although these changes are within a threshold, as noted by Kristan Lansbery, PhD, JD, director and patent attorney at Regeneron Pharmaceuticals, many of the quality attributes remain the same. The difficulty, she states, “is that a follow-on product can only compare to the originator's final product. The biosimilar developer has no knowledge of the originator's predetermined ranges for quality attributes, and although they can acquire the product and run tests to analyze and identify quality attributes, independently produced follow-on biologics have different qualities.”
The FDA released a draft guidance document in January 2017 around how manufacturers should demonstrate interchangeability of a product and the data that it wanted developers to submit. However, there have been many concerns and questions submitted to the FDA from industry members.
Wong discussed some concerns stakeholders have about the document, including:
According to Wong, many of the questions surrounding a biosimilar achieving interchangeability will be addressed in the finalized guidance by the FDA, “which we can look forward to seeing, hopefully, in 2019.”
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.